SLU-PP-332

At a glance

Standard Protocol

Alternative Titration 1 - 60mg Week Max Oral Tabs

Alternative Titration 2 - 80mg Week Max Oral Tabs

Alternative Titration 3 - 100mg week Max Oral Tabs

Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (ERR Agonist); route Subcutaneous/Oral; timing Morning / Pre-Workout. Unapproved or source-dataset dosing tables are hypotheses, not recommendations.

• Mild lethargy post-dose during initiation: the metabolic reprogramming demands cellular resources during the gene expression transition phase; most pronounced in weeks 1-2 as new mitochondrial proteins are being synthesized; resolves as the oxidative capacity becomes established.
• Injection site irritation: redness, soreness, minor swelling at subcutaneous administration site; standard response.
• Insomnia or sleep disruption: ERR agonism and mitochondrial biogenesis drive upregulated metabolic rate; dosing in the afternoon or evening may produce difficulty falling asleep; morning and pre-workout dosing protocols exist specifically to prevent this.
• GI discomfort with oral tablet formulations: nausea, abdominal bloating, or loose stools at higher oral doses; the split oral dosing schedules (morning, 11am, 2pm) distribute the load to reduce peak GI exposure.
• Potential cardiovascular effects: ERRα's cardiac expression means SLU-PP-332 has cardiac metabolic activity; in healthy subjects this is likely beneficial but cardiac effects in diseased tissue are not characterized.
• Theoretical ERR-mediated cancer cell activation: the most significant theoretical adverse concern; the same transcriptional programs SLU-PP-332 activates for metabolic benefit in healthy tissue overlap with pro-tumor ERRα programs in oncological contexts.
• Unknown long-term adverse effects: no published Phase 1 human clinical trial data exists as of mid-2026; the complete human adverse event profile is genuinely uncharacterized beyond animal studies and early research observation.
• No estrogenic side effects: despite the "estrogen-related" nomenclature, SLU-PP-332 does not activate ERα or ERβ estrogen receptors and produces no estrogenic effects (gynecomastia, feminization, HPTA suppression).

• Active malignancy: ERRα is overexpressed in multiple cancers including breast, ovarian, and prostate cancer where it promotes tumor survival, metastasis, and OXPHOS upregulation that supports tumor bioenergetics; SLU-PP-332's ERR agonism could activate these same pro-tumor transcriptional programs.
• Hormone-sensitive cancers (breast, ovarian, prostate, endometrial): while ERRs are mechanistically distinct from estrogen receptors, they share pathway convergence in hormone-sensitive tissues and have documented roles in driving progression of these cancers.
• Pregnancy: ERR nuclear receptors are involved in trophoblast development and placental energy metabolism; exogenous ERR agonism during pregnancy is not established as safe.
• Breastfeeding: no safety data established.
• Known hypersensitivity to SLU-PP-332 or related quinazolinone compounds.
• Severe cardiac arrhythmia or decompensated heart failure: ERRα is highly expressed in cardiac tissue and drives the cardiac OXPHOS gene program; in decompensated heart failure where cardiac energy metabolism is already dysregulated, supraphysiological ERR agonism may produce uncharacterized and potentially adverse effects.
• Pediatric use: ERR receptors are involved in developmental biology; safety in children is not established.
• Concurrent use with other PGC-1α or ERR-modulating agents: the magnitude of overlapping mitochondrial biogenesis stimulation from multiple simultaneous pathway activators is not characterized.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/?term=SLU-PP-332